Premier Diagnostic Health Services Inc.
CNSX : PDH

Premier Diagnostic Health Services Inc.

July 25, 2014 14:27 ET

Premier Diagnostic Health Services Inc. Announces New Chair of the Board

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 25, 2014) -

NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA.

Premier Diagnostic Health Services Inc. ("Premier" or the "Company") (CSE:PDH) announces that the Board of Directors has appointed distinguished clinician and scientist Dr. Simon Sutcliffe, M.D., FRCP, FRCP(C), FRCR as the new Non-Executive Chair of the Board, effective July 24, 2014. Dr. Sutcliffe joined Premier's board as of June 1, 2014. He is highly regarded as a leader in cancer control.

Dr. Sutcliffe's training has encompassed internal medicine, scientific research, medical and radiation oncology in Canada, the USA, the UK and South Africa. Dr. Sutcliffe has held staff appointments at St. Bartholomew's Hospital (London, England), Princess Margaret Hospital/Ontario Cancer Institute and the BC Cancer Agency. Dr. Sutcliffe was awarded the Queen Elizabeth 50th Jubilee Gold Medal in 2003, and the Terry Fox Award of the BC Medical Association in 2009 for his lifetime services to cancer control.

Dr. Sutcliffe acted as the President and CEO of the BC Cancer Agency from 2000 to 2009, and prior to that he was President and CEO of the Ontario Cancer Institute/Princess Margaret Hospital from 1994 to 1996. He chairs the Board of the Institute for Health Systems Transformation and Sustainability; is President of the International Cancer Control Congress Association, the International Network for Cancer Treatment and Research-Canada Branch (Two Worlds Cancer Collaboration); is a Senior Advisor to the Terry Fox Research Institute and is Chief Medical Officer for QuBiologics Inc. and Omnitura Inc. He is a past Chair of the Board of the Canadian Partnership Against Cancer (CPAC, 2009-2012), the Michael Smith Foundation for Health Research (MSFHR, 2006-7) and has served on the Boards of CPAC, MSFHR and Genome BC. He is an Adjunct Clinical Professor at the University of British Columbia and an Associate Scientist with the Michael Smith Genome Sciences Centre at the BC Cancer Agency.

Ian D. Robertson previously served in the role of interim Non-Executive Chair of the Board and remains a director of the Company.

Share Issuance

The Company further announces that, subject to CSE approval, it will issue an aggregate of 1,238,486 Common shares at a deemed price of $0.05 per share as securities for debt to two creditors. One of the creditors is a private company controlled by the spouse of a director of Premier. The shares will be subject to a hold period as applicable under securities laws.

About Premier Diagnostic Health Services Inc. ("PDHS")

PDHS is a Canadian company that provides, through its subsidiaries, advanced medical diagnostic tools using PET/CT technology and/or MRI technology and related diagnostic skills in Canada and in the People's Republic of China, in partnership with local medical professionals, public and private investors, hospitals and clinics. The Company's mission is to provide physicians and other health care professional with exceptional diagnostic information that will assist them in making medical decisions that lead to better outcomes for their patients. The Company's approach involves building long-term relationships regarding management, quality, and financial services that are necessary to build, operate and grow the diagnostic capacity and capability of hospitals and clinics worldwide.

On behalf of the Board of Directors

Denis Tusar, President and CEO

The Canadian Stock Exchange (CSE) has not reviewed the adequacy or the accuracy of the contents of this document. Company information can be viewed here: www.cnsx.ca. Further information regarding the Company can be found on SEDAR at ww.sedar.com.

Contact Information